item management s discussion and analysis of financial condition and results of operations during and  the company generated revenues from product sales  but continues to be dependent upon external financing  interest income  and research and development contracts to pursue its intended business activities 
the company has not been profitable since inception and has incurred a cumulative net loss of  through december  losses have resulted principally from costs incurred in research activities aimed at identifying and developing the company s product candidates  clinical research studies  merger and acquisition costs  the write off of purchased research and development  and general and administrative expenses 
the company expects to incur additional operating expenses over the next several years as the company s research and development and clinical trial programs continue 
the company s ability to achieve profitability is dependent on the level of revenues from the sale of drug substance to support lotemax and alrex  coupled with its ability to develop and obtain regulatory approvals for its product candidates  to enter into agreements for product development and commercialization with strategic corporate partners and to develop or acquire the capacity to manufacture and sell its products 
see management s discussion and analysis of financial condition and results of operations liquidity and capital resources 
results of operations years ended december  and revenues from sale of product increased  or  from  in to  in the increase resulted from increased market shares for the company s products as well as a full year of revenue for versus three quarters in as product sales commenced in april additionally  the company recorded license income of  for the year ended december  the license income was primarily generated from a non recurring payment received by the company in exchange for the transfer of certain drug technology 
cost of goods sold increased  or  from  in to  in the increase reflects the high product revenue in versus cost of goods sold includes the cost of the active drug substance and royalty payments 
total operating expenses increased  or  from  in to  in the increase in operating expenses is due to increases in selling  general administrative expenses  research and development expenses and depreciation 
net research and development expenses increased by  or  from  in to  in the increase in r d expense is primarily due to higher outside consulting costs associated with the phase ii testing of the company s dexanabinol product and on compounds in various stages of clinical and preclinical testing 
selling  general and administrative expenses increased by  or  from  in to  in the increase is primarily due to higher wage and benefits costs and increased investor relations activities partially offset by reduced professional fees and reduced travel costs 
depreciation and amortization expenses increased by  or  from  in to  in  reflecting increased depreciation expense related to laboratory equipment purchases in interest and other income  net of interest and other expenses  decreased by  or  from  in to  in the decline is principally due to lower interest income as a result of lower average cash balances 
years ended december  and during the year ended december   the company reported revenues from sale of product for the first time 
product sales commenced in april  and revenues totaled  for the period 
additionally  the company recorded license income of  for the year ended december  for the year ended december  
the license income was primarily generated from a non recurring payment received by the company in exchange for the transfer of certain drug technology 
cost of goods sold for the year ended december  totaled  cost of goods sold includes the cost of the active drug substance and royalty payments 
total operating expenses decreased  or  from  in to  in the decrease in operating expenses is primarily due to a decrease in research and development expenses 
net research and development expenses decreased by  or  from  in to  in the decrease in r d expense is primarily due to the closure of the company s r d facilities in florida during the fourth quarter of  a lower than anticipated level of research and development expenditures at the company s israel facility and reduced regulatory expenses resulting from the granting of waivers for fees previously paid to the fda 
selling  general and administrative expenses decreased by  or  from  in to  in the decrease is primarily due to costs incurred by the company during under marketing agreements to supply bausch lomb pharmaceuticals  inc blp with certain specified quantities of loteprednol etabonate le 
these quantities of le  totaling  were purchased during for use in testing  manufacturing and various marketing activities  and were charged to results of operations in no such amounts were incurred in patent expenses increased by  or  from  in to  in this increase is due to the timing of completion of certain patent applications 
depreciation and amortization expenses increased by  or  from  in to  in  reflecting a higher level of purchases of fixed assets during interest and other income  net of interest and other expenses  increased by  or  from  in to  in interest and other income  net  increased principally as a result of higher average cash balances during liquidity and capital resources while the company has received revenues for and through the sale of its approved products  it has incurred operating losses since its inception 
at december   the company had an accumulated deficit of  the company has financed its operations with public and private offerings of securities  advances and other funding pursuant to a marketing agreement with blp  research contracts  license fees  royalties and sales  and interest income 
the company had working capital of million  including cash and cash equivalents of million  as of december  in december  the company obtained a million equity line of credit with a single institutional investor 
under terms of the equity line of credit agreement  the company issued  shares of its common stock and  warrants to purchase shares of its common stock to such investor for consideration of million  net of fees 
during  the company received additional equity of million from the exercise of warrants to purchase the company s common stock 
during the first quarter of  the company completed private placements of  shares of common stock that generated million in gross proceeds 
also during the first quarter of  under terms of the equity line of credit agreement  the company issued  shares of its common stock and warrants to purchase  shares of its common stock to the investor for consideration of million  net of fees 
further  during the first quarter of  the company received additional equity of million from the exercise of options and warrants to purchase the company s common stock 
management believes that existing cash and cash equivalents  including the proceeds from the first quarter of described above  combined with anticipated cash inflows from investment income  the equity line of credit  r d grants and proceeds from sales of the drug substance for lotemax and alrex to blp will be sufficient to support the company s continuing operations 
the company is continuing to actively pursue various funding options  including additional equity offerings  strategic corporate alliances  business combinations and the establishment of product related research and development limited partnerships  to obtain the additional financing that would be required to continue the development of its products and bring them to commercial markets 
during  the company raised equity of million through the issuance of convertible preferred stock and warrants  received additional equity of million from the exercise of options and warrants to purchase the company s common stock and million under terms of the equity line of credit agreement 
all net proceeds were available to fund the company s operations 
cumulative advances from blp as of december  totaled million 
blp is entitled to recoup the advances by withholding certain amounts from the proceeds payable to the company for purchases of the active drug substance used in the production of lotemax  alrex and line extension products 
as of december   the outstanding advances from blp amounted to million 
the company may be obligated to repay such advances if it is unable to supply blp with certain specified quantities of the active drug substance 
the year during  the company completed an assessment of the potential impact of the year on the ability of the company s computerized information systems to accurately process information that may be date sensitive 
the company went through the year rollover with no disruptions to its business 
there were no failures of systems deemed critical or essential 
the costs of addressing this issue did not have a material adverse impact on the company s financial position 
the company has not experienced any year issues that effect third parties  including the company s current and prospective suppliers 

